CytomX

QSP Model of a Masked Tumor-Activated Antibody Video Abstract

Video accompanying Stroh et al. “Quantitative Systems Pharmacology Model of a Masked, Tumor-Activated Antibody.” CPT Pharmacometrics Syst. Pharmacol. (2019). doi: 10.1002/psp4.12448

Nonclinical Development of Probody Drug Conjugates

Richardson, J. (2019, September) Nonclinical Development of Probody Drug Conjugates. Presented at the Charles River 25^th Annual Biotech Symposium: Biotechnology-Derived Therapeutics Perspectives on Nonclinical Development. Carlsbad, CA.

Designing In and Around Tolerability Considerations for Immunotherapy Combinations

Clinical Pharmacology & Therapeutics; Stroh, M.; April 2018.

Quantitative Systems Pharmacology Model of a Masked, Tumor-Activated Antibody

CPT: Pharmacometrics and Systems Pharmacology; Stroh, M., et al; May 2019.

In vivo imaging of protease activity by Probody therapeutic activation

Biochimie; Vasiljeva O, et al; November 2015.

Imaging a functional tumorigenic biomarker in the transformed epithelium

Proceedings of the National Academy of Sciences USA; LeBeau, A. et al; January 2013

Identification of protease exosite-interacting peptides that enhance substrate cleavage kinetics

Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases

Journal of Controlled Release; Erster, O. et al; August 2012

Emerging principles in protease-based drug discovery

Nature Reviews Drug Discovery; Drag, M. et al; September 2010

Evolutionary optimization of peptide substrates for proteases that exhibit rapid hydrolysis kinetics

Biotechnology and Bioengineering; Boulware K, et al; June 2010.